Shares of Retrophin (RTRX) surged Wednesday after announcing positive results for its drug that treats a rare kidney disease. In the Phase II study, patients responded to treatment at more than twice the rate of patients receiving a control drug. Retrophin will meet with the U.S. Food and Drug Administration to plan the critical Phase III study. Currently, there are no approved drugs for the rare disease, which causes scarring of the kidneys and leads to end-stage kidney disease.
More from Video
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.